Johnson & Johnson (JNJ) Shares Sold by Highland Capital Management LLC

Highland Capital Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.9% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 151,967 shares of the company’s stock after selling 26,571 shares during the period. Johnson & Johnson makes up approximately 1.4% of Highland Capital Management LLC’s holdings, making the stock its 11th biggest position. Highland Capital Management LLC’s holdings in Johnson & Johnson were worth $18,440,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. BlackRock Inc. increased its position in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Boston Partners increased its position in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares during the last quarter. Bank of Montreal Can increased its position in shares of Johnson & Johnson by 36.1% during the 2nd quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares during the last quarter. Summit Trail Advisors LLC increased its position in shares of Johnson & Johnson by 11,692.6% during the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,752,841 shares during the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Johnson & Johnson by 55.1% during the 4th quarter. Mackenzie Financial Corp now owns 4,243,594 shares of the company’s stock valued at $592,915,000 after purchasing an additional 1,507,278 shares during the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

Several research firms have recently commented on JNJ. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research report on Friday, September 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, July 15th. Finally, Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $143.91.

In related news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson stock opened at $139.10 on Monday. The company has a market capitalization of $370.70 billion, a P/E ratio of 19.05, a PEG ratio of 2.19 and a beta of 0.70. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.04. The company had revenue of $20.83 billion during the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.83 EPS. Analysts forecast that Johnson & Johnson will post 8.14 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.59%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s dividend payout ratio is 49.32%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Trading Strategy Methods for Individual Investors

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply